ReviewOphthalmology and therapy2019
Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment.
Review in Ophthalmology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 64 citations in OpenAlex.
- Results of adjunctive homogenate amniotic membrane eye drops in the management of refractory ocular surface disease with dry eye manifestations.International ophthalmology · 2026Article
- Article
- Letter to editor on "Efficacy and safety of minor salivary gland transplantation for the treatment of severe dry eye disease: a single-arm meta-analysis".International journal of surgery (London, England) · 2026Article
- Autoimmune Diseases of the Eyelid Skin: Molecular Pathways, Clinical Manifestations, and Therapeutic Insights.International journal of molecular sciences · 2025Review
- Incidence and prevalence of mucous membrane pemphigoid with ocular involvement: a retrospective analysis using the TriNetX database.Eye (London, England) · 2025Article
- Mucous membrane pemphigoid with ocular involvement in a patient diagnosed previously with mucosal-dominant pemphigus vulgaris: A case report.JAAD case reports · 2025Article
- Incidence and Outcomes of Cataract in Eyes with Ocular Cicatricial Pemphigoid.Ocular immunology and inflammation · 2025Article
- Challenges and advances in ocular mucous membrane pemphigoid (OMMP); from pathogenesis to treatment strategies.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- Ocular Cicatricial Pemphigoid in a Healthy Elderly Male Filipino Patient.Acta medica Philippina · 2025Article
- Ocular surface glycocalyx in health and disease.Frontiers in cell and developmental biology · 2025Review
- Impact of Exposomes on Ocular Surface Diseases.International journal of molecular sciences · 2023Review
- Application of biomaterials and nanotechnology in corneal tissue engineering.The Journal of international medical research · 2023Review
- The Multifold Etiologies of Limbal Stem Cell Deficiency: A Comprehensive Review on the Etiologies and Additional Treatment Options for Limbal Stem Cell Deficiency.Journal of clinical medicine · 2023Review
- Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art.Biotech (Basel (Switzerland)) · 2023Review
- Diagnostic Algorithm for Surgical Management of Limbal Stem Cell Deficiency.Diagnostics (Basel, Switzerland) · 2023Article
- Diagnostic and prognostic values of conjunctival and oral biopsies analyzed by direct immunofluorescence in patients with mucous membrane pemphigoid.Frontiers in medicine · 2023Article
- Anti-Laminin 332-Type Mucous Membrane Pemphigoid.Biomolecules · 2022Review
- Perioperative Management and Long-Term Outcomes in Ocular Cicatricial Pemphigoid Patients Undergoing Cataract Surgery.Oxidative medicine and cellular longevity · 2022Article
- Association Between Skin Findings and Ocular Signs in Rosacea.Turkish journal of ophthalmology · 2021Article
- Tofacitinib for refractory ocular mucous membrane pemphigoid.American journal of ophthalmology case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 5 countries.
Funding
Abstract
Mucous membrane pemphigoid (MMP) is a systemic cicatrizing autoimmune disease that primarily affects orificial mucous membranes, such as the conjunctiva, the nasal cavity, the oropharynx, and the genitalia. Ocular involvement occurs in about 70% of all MMP cases. Ocular MMP (OcMMP) also encompasses the conditions linear immunoglobulin A disease, mucosal dominated epidermolysis bullosa acquisita, and anti-laminin 332/anti-epiligrin/anti-laminin 5 pemphigoid. It is a complex clinical entity that may lead to ocular surface failure and result in inflammatory and infectious complications, as well as potentially devastating visual loss. Early diagnosis and appropriate treatment are of paramount importance and require a high level of expertise as this condition can be extremely challenging to diagnose and treat even for experienced clinicians. In this review we provide an up-to-date insight on the pathophysiology of OcMMP, with an emphasis on the current state of its diagnostics and therapeutics. Our the aim is to increase our understanding of OcMMP and highlight modern diagnostic and therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.